Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Am J Transplant. 2017 Jan 27;17(5):1193–1203. doi: 10.1111/ajt.14141

Figure 7. Rejection histology when treated with AL-579.

Figure 7

Figure 7

A) An example of rejection with belatacept monotherapy (ACR IIB) with significant infiltration and glomerulopathy. B) Rejection while under treatment with AL-579 and belatacept (ACR 1A) again with significant infiltration, however without vasculitis.